BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12503198)

  • 1. New treatment option for postmenopausal women with early breast cancer.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):617. PubMed ID: 12503198
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 3. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
    Hannaford M
    Nurse Pract; 1997 Mar; 22(3):195-6, 201-2. PubMed ID: 9078523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy in postmenopausal breast cancer.
    Ingle JN
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):480S-5S. PubMed ID: 12538504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU; Vergote I; Sainsbury R
    Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A better medication for treating breast cancer?
    Johns Hopkins Med Lett Health After 50; 2002 May; 14(3):3. PubMed ID: 12004835
    [No Abstract]   [Full Text] [Related]  

  • 10. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toremifene and letrozole for advanced breast cancer.
    Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
    [No Abstract]   [Full Text] [Related]  

  • 12. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D; Thuerlimann B
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
    Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
    Forciniti S
    Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
    [No Abstract]   [Full Text] [Related]  

  • 17. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
    Hargis JB; Nakajima ST
    Cancer Invest; 2006 Mar; 24(2):174-7. PubMed ID: 16537187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract]   [Full Text] [Related]  

  • 19. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci LC
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
    [No Abstract]   [Full Text] [Related]  

  • 20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.